{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093721","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2026-08-11T11:09:16+00:00","discovered_at":"2026-08-11T11:10:00.404220+00:00","generated_at":"2026-08-11T11:10:07.360226+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CVRx CRO Robert John departs; Paul Verrastro named interim head of sales","bullets":["Robert John terminated as CRO effective Aug 10, 2026; eligible for severance under employment agreement.","Paul Verrastro named Interim Head of Sales, effective immediately; leads search for permanent successor.","Verrastro has 30+ years med-device sales experience; former CMO at CVRx, previously Guidant, Boston Scientific, Medtronic.","CEO Kevin Hykes cites revised commercial outlook and need to improve commercial execution for the change."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093721","json":"https://secwatch.observer/filing/0001104659-26-093721.json","markdown":"https://secwatch.observer/filing/0001104659-26-093721.md","text":"https://secwatch.observer/filing/0001104659-26-093721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926093721/0001104659-26-093721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926093721/tm2622791d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:10:07.360226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}